Literature DB >> 40881

Large-scale production and physicochemical characterization of human immune interferon.

M P Langford, J A Georgiades, G J Stanton, F Dianzani, H M Johnson.   

Abstract

Large-scale production of crude high-titered (10(2.3) to 10(4) U/ml) human immune interferon (type II) was carried out in roller bottle cultures of human peripheral lymphocytes by using the T-cell mitogen staphylococcal enterotoxin A. Over 99% of human immune interferon was destroyed by pH 2 or heat at 56 degrees C for 1 h. The interferon was not neutralized by antibody to human leukocyte interferon. The kinetics of development of the antiviral state were slow for immune interferon relative to those for leukocyte interferon. Ultrogel AcA 54 chromatography of crude or the concentrated interferon resulted in two peaks of activity, a major one (87% of recovered activity) with a molecular weight of 40,000 to 46,000 and a minor peak of molecular weight 65,000 to 70,000. The column elution buffer consisting of 18% ethylene glycol and 1 M NaCl in phosphate-buffered saline resulted in at least 100% recovery of added interferon. The data suggest, then, that the interferon produced under large-scale conditions was immune (type II). The efficiency of the production was comparable to that described for large-scale production of human leukocyte interferon. Our large-scale production system for human immune interferon offers a feasible approach to preparation of large quantities of purified immune interferon for structure studies, antibody production, and clinical application.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 40881      PMCID: PMC414571          DOI: 10.1128/iai.26.1.36-41.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Heterogeneity of purified mouse interferons.

Authors:  E Knight
Journal:  J Biol Chem       Date:  1975-06-10       Impact factor: 5.157

2.  Preparation of human leukocyte interferon for clinical use.

Authors:  K Cantell; S Hirvonen
Journal:  Tex Rep Biol Med       Date:  1977

3.  Purification and characterization of mouse interferon with novel affinity sorbents.

Authors:  M W Davey; E Sulkowski; W A Carter
Journal:  J Virol       Date:  1976-02       Impact factor: 5.103

4.  Differences in mouse interferons according to cell source and mode of induction.

Authors:  N Maehara; M Ho; J A Armstrong
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

Review 5.  Mitogen and antigen induction of interferon in vitro and in vivo.

Authors:  L B Epstein
Journal:  Tex Rep Biol Med       Date:  1977

6.  Human leukocyte interferon: production, purification to homogeneity, and initial characterization.

Authors:  M Rubinstein; S Rubinstein; P C Familletti; R S Miller; A A Waldman; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Purification of mouse interferon by sequential affinity chromatography on poly(U)--and antibody--agarose columns.

Authors:  J De Maeyer-Guignard; M G Tovey; I Gresser; E De Maeyer
Journal:  Nature       Date:  1978-02-16       Impact factor: 49.962

8.  Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon.

Authors:  J L Crane; L A Glasgow; E R Kern; J S Youngner
Journal:  J Natl Cancer Inst       Date:  1978-09       Impact factor: 13.506

9.  Two antigenically distinct species of human interferon.

Authors:  E A Havell; B Berman; C A Ogburn; K Berg; K Paucker; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

10.  Purification and characterization of human leukocyte interferon components.

Authors:  E T Törmä; K Paucker
Journal:  J Biol Chem       Date:  1976-08-25       Impact factor: 5.157

View more
  24 in total

1.  Localization of an antiviral site on the pregnancy recognition hormone, ovine trophoblast protein 1.

Authors:  C H Pontzer; T L Ott; F W Bazer; H M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  Source of heterogeneity in secreted interferon-gamma. A study on products of translation in vitro.

Authors:  N J Bulleid; E Curling; R B Freedman; N Jenkins
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

3.  Enhancement of basophil chemotaxis in vitro by virus-induced interferon.

Authors:  M A Lett-Brown; M Aelvoet; J J Hooks; J A Georgiades; D O Thueson; J A Grant
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

4.  Cell cultures producing human interferon.

Authors:  P C Familletti; S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

5.  Radiation inactivation of human gamma-interferon: cellular activation requires two dimers.

Authors:  J A Langer; A Rashidbaigi; G Garotta; E Kempner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

6.  Kinetics of human immune interferon production and blastogenesis.

Authors:  W S Ng; M H Ng; M Inoue; Y H Tan
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

7.  Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.

Authors:  B Y Rubin; S L Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

8.  Partial purification and characterization of human gamma (immune) interferon.

Authors:  Y K Yip; R H Pang; C Urban; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Interleukin 2 enhances natural killer cell activity through induction of gamma interferon.

Authors:  D A Weigent; G J Stanton; H M Johnson
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

10.  Streptococcus pneumoniae cocultured with fibroblasts enhances both interferon production and cytotoxic activity by lymphocytes.

Authors:  D A Weigent; S Baron; G J Stanton
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.